{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:41Z","timestamp":1793352941952,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtha.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:09:02Z","timestamp":1787155742000},"page":"3932-3938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-2225","authenticated-orcid":false,"given":"Milan","family":"Vuj\u010di\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Maduni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasminka","family":"Jakeli\u0107 Pite\u0161a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Petri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-8529","authenticated-orcid":false,"given":"Davor","family":"Galu\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ena","family":"Rankovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-2336","authenticated-orcid":false,"given":"Ana","family":"Boban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.009_bib1","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.009_bib2","first-page":"628","article-title":"Acquired von Willebrand syndrome: a comprehensive review and a Nordic perspective","volume":"52","author":"Zetterberg","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.009_bib3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/hae.14648","article-title":"Acquired von Willebrand syndrome and lymphoid neoplasms: a review of malignancy management, and propositions of practical recommendations","volume":"28","author":"Nicol","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.009_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.009_bib5","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29. Identifier NCT05500807, emicizumab for severe Von Willebrand Disease (VWD) and VWD\/Hemophilia A. https:\/\/clinicaltrials.gov\/study\/NCT05500807. [accessed Jul 26]"},{"key":"10.1016\/j.jtha.2026.08.009_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.009_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00277-016-2650-x","article-title":"Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias","volume":"95","author":"Dicke","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2026.08.009_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0030-1270069","article-title":"Acquired von Willebrand syndrome associated with hypothyroidism: a mild bleeding disorder to be further investigated","volume":"37","author":"Federici","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.009_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.009_bib10","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/eurheartj\/ehad340","article-title":"Effectiveness of aortic valve replacement in Heyde syndrome: a meta-analysis","volume":"44","author":"Goltstein","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.009_bib11","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.009_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2005.01.031","article-title":"Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome","volume":"66","author":"Federici","year":"2005","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jtha.2026.08.009_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S2468-1253(21)00262-4","article-title":"Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis","volume":"6","author":"Goltstein","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2026.08.009_bib14","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.08.009_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/a-2384-3585","article-title":"Final analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy","volume":"125","author":"Shima","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.009_bib16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1055\/s-0038-1660481","article-title":"Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis of VWD and AVWS","volume":"45","author":"Stufano","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.009_bib17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"22","key":"10.1016\/j.jtha.2026.08.009_bib18","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1182\/bloodadvances.2025017144","article-title":"Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A","volume":"9","author":"Schimansky","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.009_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MBC.0000000000001371","article-title":"Management of gastrointestinal bleeding in a patient with type 3 von Willebrand disease and inhibitors to von Willebrand factor: a case report","volume":"36","author":"Rankovi\u0107","year":"2025","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:01:52Z","timestamp":1793350912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538783626005313"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}